Aridis Pharmaceuticals Inc (ARDS) Receives $28.25 Average Target Price from Analysts

Share on StockTwits

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has been assigned an average rating of “Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $28.25.

Several research analysts have weighed in on ARDS shares. Zacks Investment Research lowered shares of Aridis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, January 7th. ValuEngine lowered shares of Aridis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $25.00 price target on shares of Aridis Pharmaceuticals in a report on Tuesday, November 13th. Finally, Maxim Group set a $25.00 price target on shares of Aridis Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 4th.

ARDS stock traded down $0.21 during mid-day trading on Friday, hitting $8.15. 1,607 shares of the company were exchanged, compared to its average volume of 2,432. Aridis Pharmaceuticals has a twelve month low of $7.59 and a twelve month high of $13.85.

Aridis Pharmaceuticals (NASDAQ:ARDS) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($1.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.92). The business had revenue of $1.02 million for the quarter, compared to the consensus estimate of $0.33 million. Equities analysts forecast that Aridis Pharmaceuticals will post -4.2 earnings per share for the current fiscal year.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Featured Article: Marijuana Stocks

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply